CN111518768B - 一种适用于lmh细胞贴壁培养的低血清培养基及其制备方法 - Google Patents
一种适用于lmh细胞贴壁培养的低血清培养基及其制备方法 Download PDFInfo
- Publication number
- CN111518768B CN111518768B CN202010288501.XA CN202010288501A CN111518768B CN 111518768 B CN111518768 B CN 111518768B CN 202010288501 A CN202010288501 A CN 202010288501A CN 111518768 B CN111518768 B CN 111518768B
- Authority
- CN
- China
- Prior art keywords
- acid
- sodium
- chloride
- sulfate
- lmh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000001963 growth medium Substances 0.000 title abstract description 30
- 238000002360 preparation method Methods 0.000 title description 9
- 238000012136 culture method Methods 0.000 title description 2
- 210000002966 serum Anatomy 0.000 claims abstract description 30
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 16
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims abstract description 12
- JXXCENBLGFBQJM-FYZOBXCZSA-N [(2r)-3-carboxy-2-hydroxypropyl]-trimethylazanium;chloride Chemical compound [Cl-].C[N+](C)(C)C[C@H](O)CC(O)=O JXXCENBLGFBQJM-FYZOBXCZSA-N 0.000 claims abstract description 9
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 claims abstract description 8
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 claims abstract description 8
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000001530 fumaric acid Substances 0.000 claims abstract description 8
- 229960003151 mercaptamine Drugs 0.000 claims abstract description 8
- 229960002718 selenomethionine Drugs 0.000 claims abstract description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229920002307 Dextran Polymers 0.000 claims abstract description 7
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims abstract description 6
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims abstract description 6
- 229960003237 betaine Drugs 0.000 claims abstract description 6
- 229940046374 chromium picolinate Drugs 0.000 claims abstract description 6
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 claims abstract description 6
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 claims abstract description 6
- 229960001327 pyridoxal phosphate Drugs 0.000 claims abstract description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 12
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims description 10
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 10
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 8
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 8
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 8
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 claims description 8
- 229940088594 vitamin Drugs 0.000 claims description 8
- 229930003231 vitamin Natural products 0.000 claims description 8
- 235000013343 vitamin Nutrition 0.000 claims description 8
- 239000011782 vitamin Substances 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 6
- 235000019743 Choline chloride Nutrition 0.000 claims description 6
- 108010024636 Glutathione Proteins 0.000 claims description 6
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 6
- 229960003178 choline chloride Drugs 0.000 claims description 6
- 229960003180 glutathione Drugs 0.000 claims description 6
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims description 6
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 6
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 5
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 5
- 239000011683 manganese gluconate Substances 0.000 claims description 5
- 235000014012 manganese gluconate Nutrition 0.000 claims description 5
- 229940072543 manganese gluconate Drugs 0.000 claims description 5
- OXHQNTSSPHKCPB-IYEMJOQQSA-L manganese(2+);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Mn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OXHQNTSSPHKCPB-IYEMJOQQSA-L 0.000 claims description 5
- 229930182817 methionine Natural products 0.000 claims description 5
- 229940107700 pyruvic acid Drugs 0.000 claims description 5
- 229960002477 riboflavin Drugs 0.000 claims description 5
- 235000019192 riboflavin Nutrition 0.000 claims description 5
- 239000002151 riboflavin Substances 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- 229930091371 Fructose Natural products 0.000 claims description 4
- 239000005715 Fructose Substances 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004473 Threonine Substances 0.000 claims description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 4
- 235000013734 beta-carotene Nutrition 0.000 claims description 4
- 239000011648 beta-carotene Substances 0.000 claims description 4
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 4
- 229960002747 betacarotene Drugs 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 4
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- 235000011148 calcium chloride Nutrition 0.000 claims description 4
- 239000004227 calcium gluconate Substances 0.000 claims description 4
- 235000013927 calcium gluconate Nutrition 0.000 claims description 4
- 229960004494 calcium gluconate Drugs 0.000 claims description 4
- 239000001506 calcium phosphate Substances 0.000 claims description 4
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 4
- 229910000365 copper sulfate Inorganic materials 0.000 claims description 4
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 4
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 4
- 229960002743 glutamine Drugs 0.000 claims description 4
- 229960000890 hydrocortisone Drugs 0.000 claims description 4
- 229960000367 inositol Drugs 0.000 claims description 4
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 4
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 claims description 4
- RUTXIHLAWFEWGM-UHFFFAOYSA-H iron(3+) sulfate Chemical compound [Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUTXIHLAWFEWGM-UHFFFAOYSA-H 0.000 claims description 4
- 229910000360 iron(III) sulfate Inorganic materials 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- 229960004488 linolenic acid Drugs 0.000 claims description 4
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 4
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 claims description 4
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 claims description 4
- 229910000150 monocalcium phosphate Inorganic materials 0.000 claims description 4
- 235000019691 monocalcium phosphate Nutrition 0.000 claims description 4
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 4
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 4
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 4
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 claims description 4
- 229960003531 phenolsulfonphthalein Drugs 0.000 claims description 4
- 239000001103 potassium chloride Substances 0.000 claims description 4
- 235000011164 potassium chloride Nutrition 0.000 claims description 4
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 4
- 235000007715 potassium iodide Nutrition 0.000 claims description 4
- 235000010333 potassium nitrate Nutrition 0.000 claims description 4
- 239000004323 potassium nitrate Substances 0.000 claims description 4
- 229960003387 progesterone Drugs 0.000 claims description 4
- 239000000186 progesterone Substances 0.000 claims description 4
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 4
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 4
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 4
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 4
- 239000011607 retinol Substances 0.000 claims description 4
- 229960003471 retinol Drugs 0.000 claims description 4
- 235000020944 retinol Nutrition 0.000 claims description 4
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 4
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 235000002639 sodium chloride Nutrition 0.000 claims description 4
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 4
- 239000011781 sodium selenite Substances 0.000 claims description 4
- 235000015921 sodium selenite Nutrition 0.000 claims description 4
- 229960001471 sodium selenite Drugs 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 229940044175 cobalt sulfate Drugs 0.000 claims description 3
- 229910000361 cobalt sulfate Inorganic materials 0.000 claims description 3
- KTVIXTQDYHMGHF-UHFFFAOYSA-L cobalt(2+) sulfate Chemical compound [Co+2].[O-]S([O-])(=O)=O KTVIXTQDYHMGHF-UHFFFAOYSA-L 0.000 claims description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 3
- 235000020778 linoleic acid Nutrition 0.000 claims description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 4
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 claims 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims 2
- 229930182816 L-glutamine Natural products 0.000 claims 2
- 229930182844 L-isoleucine Natural products 0.000 claims 2
- HHGZUQPEIHGQST-UHFFFAOYSA-N [2-[(2-azaniumyl-2-carboxyethyl)disulfanyl]-1-carboxyethyl]azanium;dichloride Chemical compound Cl.Cl.OC(=O)C(N)CSSCC(N)C(O)=O HHGZUQPEIHGQST-UHFFFAOYSA-N 0.000 claims 2
- 229960001230 asparagine Drugs 0.000 claims 2
- 229960005261 aspartic acid Drugs 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229960002989 glutamic acid Drugs 0.000 claims 2
- 229960003136 leucine Drugs 0.000 claims 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims 2
- 229960003966 nicotinamide Drugs 0.000 claims 2
- 235000005152 nicotinamide Nutrition 0.000 claims 2
- 239000011570 nicotinamide Substances 0.000 claims 2
- 229920000136 polysorbate Polymers 0.000 claims 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 2
- 150000003890 succinate salts Chemical class 0.000 claims 2
- 239000004395 L-leucine Substances 0.000 claims 1
- 235000019454 L-leucine Nutrition 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 229910017052 cobalt Inorganic materials 0.000 claims 1
- 239000010941 cobalt Substances 0.000 claims 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 11
- 241000701792 avian adenovirus Species 0.000 abstract description 9
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 abstract description 6
- 241001465754 Metazoa Species 0.000 abstract description 4
- 229960002598 fumaric acid Drugs 0.000 abstract description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 abstract description 3
- 235000004252 protein component Nutrition 0.000 abstract description 3
- 238000012258 culturing Methods 0.000 abstract 1
- 229960002086 dextran Drugs 0.000 abstract 1
- -1 lipeptide Chemical compound 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940086735 succinate Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 54
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241001492342 Anatid alphaherpesvirus 1 Species 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 244000144977 poultry Species 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- HHGZUQPEIHGQST-RGVONZFCSA-N (2r)-2-amino-3-[[(2r)-2-amino-2-carboxyethyl]disulfanyl]propanoic acid;dihydrochloride Chemical compound Cl.Cl.OC(=O)[C@@H](N)CSSC[C@H](N)C(O)=O HHGZUQPEIHGQST-RGVONZFCSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 229960000355 copper sulfate Drugs 0.000 description 2
- 229940031098 ethanolamine Drugs 0.000 description 2
- 229940032950 ferric sulfate Drugs 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229940111688 monobasic potassium phosphate Drugs 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 229940093928 potassium nitrate Drugs 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000005206 flow analysis Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032895 transmembrane transport Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/14—Calcium; Ca chelators; Calcitonin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/35—Polyols, e.g. glycerin, inositol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/44—Thiols, e.g. mercaptoethanol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明提供了一种适用于LMH细胞贴壁培养的低血清培养基及其制备方法,属于生物制品领域,该培养基包括延胡索酸、琥珀酸盐、甜菜碱、半胱胺、右旋糖酐、磷酸吡哆醛、β‑巯基乙酸、吡啶甲酸铬、肉碱盐酸盐、力肽、硒代甲硫氨酸等物质。本发明制备的一种适用于LMH细胞贴壁培养的低血清培养基成分明确、无蛋白组分、无动物来源组分、血清用量低(2%‑3%)、病毒产量高,用于制备禽腺病毒滴度可达109TCID50/ml,用于培养LMH细胞,细胞生长均匀,不会聚团生长。
Description
技术领域
本发明涉及生物制品领域,具体涉及一种适用于LMH细胞贴壁培养的低血清培养基及其制备方法。
背景技术
2014年以来,在我国很多地区分离到Ⅰ亚群禽腺病毒。在2015年开始呈流行趋势,2017年在家禽上发病率降低,在水禽发病率升高。但从2018年3月开始在家禽发病率呈上升趋势,越来越严重,表现为包涵体肝炎和心包积水综合征,给禽类养殖和食品健康带来了重大危害。由此,我国的动物疫苗企业开始重视禽腺病毒,国家兽药信息数据库显示目前市场上尚无针对禽腺病毒的生物制品,但是申报临床试验的生物制品已达27个,其中,使用禽腺病毒作为抗原的产品有23个,这23个产品均使用贴壁LMH细胞来生产禽腺病毒。
LMH细胞(鸡肝癌细胞)系是由一位日本学者在1981年建立。LMH细胞呈典型上皮细胞特征,该细胞系保持了鸡肝细胞分化的大量表型特征,LMH细胞除了应用于禽腺病毒的制备,亦可应用于鸭瘟病毒制备。
公开号为CN 105420198 A的中国专利申请“鸡肝癌细胞系作为鸭瘟病毒宿主的应用”以LMH细胞系作为鸭瘟病毒宿主,但LMH细胞应用于生物制品疫苗生产存在很多困难。首先贴壁困难,其次易聚团生长,对血清的品质很挑剔,通常需使用10%胎牛血清的DMEM培养,生产成本昂贵,目前还没有商品化的适用于生产的低血清LMH细胞贴壁培养基,亦未见相关的LMH细胞培养基的专利。
发明内容
针对上述LMH细胞贴壁困难,易聚团生长,对血清的品质很挑剔,通常需使用10%胎牛血清的DMEM培养病毒,生产成本昂贵等缺陷,本发明提供一种适用于LMH细胞贴壁培养的低血清培养基,并针对LMH细胞,优化该培养基。
一种适用于LMH细胞贴壁培养的低血清培养基,包括如下组分:
本申请的技术方案中,核黄素为维生素类营养,右旋糖酐为多聚葡萄糖,LMH细胞有易于集聚成团生长特点,二者合并使用可使细胞不集聚生长,刺激细胞分裂,促进增殖,其中右旋糖酐不仅能给细胞提供碳源还可减少乳酸的形成;力肽促进正氮平衡,调节肌蛋白合成作用,防止细胞脱落,增强贴壁效果;β-巯基乙酸相当于胎牛血清作用,可直接刺激细胞增殖,且可使培养基中含硫化合物还原成谷胱甘肽诱导细胞增殖,使细胞高密度分裂不死亡,同时避免过氧化物对细胞的损伤;丙酮酸、抗坏血酸、谷胱甘肽3种抗氧化剂组合可替代培养基中血清白蛋白功能。甜菜碱提供甲基,部分替代胆碱合成磷脂酰胆碱,部分替代蛋氨酸合成肉碱盐酸盐,促进其他营养物质的作用,增强细胞的吸收,调节渗透压,稳定维生素,与氯化胆碱合并使用,可以避免单一使用氯化胆碱对维生素的破坏。磷酸吡哆醛为能量维生素,参与氨基酸的合成;吡啶甲酸铬参与细胞间的跨膜运输,提高了细胞对天冬氨酸、谷氨酸、甘氨酸、半胱氨酸的吸收,是葡萄糖耐量因子的组成成分,具有胰岛素作用,促进细胞对葡萄糖利用,促进葡萄糖磷酸化,促进糖原和脂肪酸的合成;亚油酸是一种主要的必需脂肪酸,可以提高维生素A,维生素D维生素E的吸收,促进细胞的分裂;葡萄糖酸锰促进细胞生长。本申请使用了3%的新生牛血清就可以达到10%胎牛血清的培养效果,生产成本低,且细胞贴壁牢固,均匀生长,不聚团。
优选的,一种适用于LMH细胞贴壁培养的低血清培养基,包括如下组分:
优选的,一种适用于LMH细胞贴壁培养的低血清培养基,应用于LMH细胞贴壁培养的同时提高病毒滴度,还需在上述配方中添加如下组分,得到一种更加适用于LMH细胞贴壁培养并提高病毒滴度的低血清培养基,硒代甲硫氨酸0.001-0.01mg/L,延胡索酸1-10mg/L,琥珀酸盐5-10mg/L,半胱胺0.05-1mg/L,肉碱盐酸盐1-20mg/L。
更为优选的,一种适用于LMH细胞贴壁培养的低血清培养基,应用于LMH细胞贴壁培养的同时提高病毒滴度,还需在上述配方中添加如下组分,得到一种更加适用于LMH细胞贴壁培养并提高病毒滴度的低血清培养基,硒代甲硫氨酸0.05mg/L,延胡索酸6mg/L,琥珀酸盐7mg/L,半胱胺0.07mg/L,肉碱盐酸盐12mg/L。
其中,半胱胺解除生长抑素对细胞的抑制生长,促进蛋白质合成,从而提高病毒产量;延胡索酸调节酸碱平衡,琥珀酸盐参与三羧酸循环;肉碱盐酸盐提高细胞对氨的耐受性;硒代甲硫氨酸提高毒株活力,增强细胞耐受力。病毒滴度由之前的108TCID50提高至109TCID50。
一种适用于LMH细胞贴壁培养的低血清培养基的制备方法,包括如下步骤:
(1)取一洁净容器将吐温80加至10ml无水乙醇中,充分搅拌至完全溶解,维生素D3、亚油酸、亚麻酸、维生素E依次加入,待每种物质完全溶解后再加入另一种物质,得到脂类营养混合物;
(2)取一洁净容器,加入600ml超纯水,依次加入葡萄糖酸锰、延胡索酸、磷酸吡哆醛、吡啶甲酸铬、力肽,用磁力搅拌器搅拌8分钟后,再依次加入:草酰乙酸、无水磷酸二氢钠、氯化钙、氯化钠、氯化钾、磷酸二氢钾、L盐酸精氨酸、天冬氨酸、胱氨酸二盐酸盐、谷氨酸、亮氨酸、异亮氨酸、甲硫氨酸、苯丙氨酸、丝氨酸、苏氨酸、色氨酸、缬氨酸、甘氨酸、硒代甲硫氨酸、无水硫酸镁、葡萄糖、果糖、葡萄糖酸钙、视黄醇,碘化钾、丙酮酸、琥珀酸盐、右旋糖酐、β-巯基乙酸、肉碱盐酸盐、烟酰胺、维生素C、生物素、氯化胆碱、乙醇胺、七水硫酸亚铁、六水合氯化镁、丙酮酸钠、丁酸钠、亚硒酸钠、柠檬酸、β-胡萝卜素、硫酸铜、硫酸铁、盐酸吡哆醇、氢化可的松、D-泛酸钙、硫酸钴、硝酸钾、力肽、肌醇、酚红、孕酮、磷酸二氢钙、谷胱甘肽、甜菜碱、半胱胺、核黄素,谷氨酰胺,用磁力搅拌器搅拌20分钟后,补液至900ml,再加入提前溶解好的脂溶性维生素混合物,再次搅拌45min,定容至1000ml,加入碳酸氢钠调节pH至7.6;
(3)用0.22微米孔径滤膜或滤芯过滤除菌即得,4℃避光保存。
一种适用于LMH细胞贴壁培养的低血清培养基的用途,及培养基在生长液和接毒维持液中的应用。
相较于现有技术,本发明的有益效果是:
(1)本申请基于禽源细胞的代谢特点,使用代谢流分析和均匀设计开发了适用于疫苗工业化生产的LMH细胞贴壁培养的低血清培养基,填补了空白,使用了2%-3%的新生牛血清就可以达到10%胎牛血清的培养效果,降低了生产成本,且细胞贴壁牢固,均匀生长,不聚团,此外病毒产量由之前的108TCID50提高至109TCID50。
(2)本发明的低血清培养基无蛋白成分,无动物来源成分,进一步降低了该培养基的生产成本;
(3)成分明确、简单,产品批间差异小,同时也简化了下游产品的纯化步骤;
(4)产品批间差异小,易于制备。
附图说明
图1是本发明所述低血清培养基(3%新生牛血清)与DMEM(10%胎牛血清)对比图;
图2是本发明所述低血清培养基接种禽腺病毒病变图片;
图3是本发明所述低血清培养基(3%新生牛血清)与DMEM(10%胎牛血清)生长曲线对比图;
具体实施方式
为了使本领域的技术人员更好地理解本发明的技术方案,下面结合具体实施例对本发明作进一步的详细说明。
一种适用于LMH细胞贴壁培养的低血清培养基的制备方法,包括如下步骤:
(1)取一洁净容器将吐温80加至10ml无水乙醇中,充分搅拌至完全溶解,维生素D3、亚油酸、亚麻酸、维生素E依次加入,待每种物质完全溶解后再加入另一种物质,得到脂类营养混合物;
(2)取一洁净容器,加入600ml超纯水,依次加入葡萄糖酸锰、延胡索酸、磷酸吡哆醛、吡啶甲酸铬、力肽,用磁力搅拌器搅拌8分钟后,再依次加入:草酰乙酸、无水磷酸二氢钠、氯化钙、氯化钠、氯化钾、磷酸二氢钾、L盐酸精氨酸、天冬氨酸、胱氨酸二盐酸盐、谷氨酸、亮氨酸、异亮氨酸、甲硫氨酸、苯丙氨酸、丝氨酸、苏氨酸、色氨酸、缬氨酸、甘氨酸、硒代甲硫氨酸、无水硫酸镁、葡萄糖、果糖、葡萄糖酸钙、视黄醇,碘化钾、丙酮酸、琥珀酸盐、右旋糖酐、β-巯基乙酸、肉碱盐酸盐、烟酰胺、维生素C、生物素、氯化胆碱、乙醇胺、七水硫酸亚铁、六水合氯化镁、丙酮酸钠、丁酸钠、亚硒酸钠、柠檬酸、β-胡萝卜素、硫酸铜、硫酸铁、盐酸吡哆醇、氢化可的松、D-泛酸钙、硫酸钴、硝酸钾、力肽、肌醇、酚红、孕酮、磷酸二氢钙、谷胱甘肽、甜菜碱、半胱胺、核黄素,谷氨酰胺,用磁力搅拌器搅拌20分钟后,补液至900ml,再加入提前溶解好的脂溶性维生素混合物,再次搅拌45min,定容至1000ml,加入碳酸氢钠调节pH至7.6;
(3)用0.22微米孔径滤膜或滤芯过滤除菌即得,4℃避光保存。
各实施例中,各成分的用量如下(单位mg):
试验例1
将LMH细胞同时接种于实施例1中制得的培养基和含有10%血清浓度的DMEM培养基中,连续贴壁培养48h,每天观察细胞的生长状态,并拍照记录,图1显示两种培养基中细胞贴壁生长,由图1可以看出,LMH细胞贴壁培养的低血清培养基优于10%血清浓度的DMEM培养基;由图2中可以看出,LMH细胞贴壁培养的低血清培养基接种禽腺病毒可使病毒滴度达到109TCID50/1mL,解决了病毒滴度低的问题;从图1和图2中可以得出一种适用于LMH细胞贴壁培养的低血清培养基能够解决鸡肝细胞易成团问题、血清用量问题、病毒滴度问题,且该培养基具有无蛋白成分、无动物来源、成本低、产品批间差异小,易于制备等优点。
试验例2
对实施例2制得的一种适用于LMH细胞贴壁培养的低血清培养基与DMEM培养基对比,研究LMH细胞贴壁生长状况,由图3知,一种适用于LMH细胞贴壁培养的低血清培养基中的细胞密度高于DMEM培养基,说明本申请的适用于一种适用于LMH细胞贴壁培养的低血清培养基有利于LMH细胞贴壁生长。
以上所述实施例仅表达了本申请的具体实施方式,其描述较为具体和详细,但并不能因此而理解为对本申请保护范围的限制。应当指出的是,对于本领域的普通技术人员来说,在不脱离本申请技术方案构思的前提下,还可以做出若干变形和改进,这些都属于本申请的保护范围。
Claims (1)
1.一种低血清培养基在LMH细胞贴壁培养中的应用,其特征在于,所述低血清培养基包括组分一或组分二;
其中,组分一包括如下组分:
草酰乙酸100
碳酸氢钠1850
无水磷酸二氢钠3500
氯化钙125
氯化钠3800
氯化钾500
磷酸二氢钾50
无水硫酸镁100
L盐酸精氨酸300
L天冬氨酸30
L天冬酰胺100
L胱氨酸二盐酸盐50
L谷氨酸5
L亮氨酸10
L异亮氨酸52
L甲硫氨酸63
L苯丙氨酸20
L丝氨酸50
L苏氨酸60
L色氨酸30
L缬氨酸80
甘氨酸46
L谷氨酰胺200
肉碱盐酸盐20
葡萄糖9000
果糖3.3
葡萄糖酸钙20
视黄醇4.5
碘化钾0.05
维生素D38
柠檬酸10
琥珀酸盐5
β-胡萝卜素0.02
力肽950
右旋糖酐4.5
β-巯基乙酸10
吐温8015
烟酰胺5
维生素E6
抗坏血酸11
生物素0.005
氯化胆碱20
乙醇胺7
七水硫酸亚铁30
六水合氯化镁160
丙酮酸钠30
丁酸钠59
亚油酸0.03
亚麻酸1
硫酸铜10
硫酸铁0.05
盐酸吡哆醇1.5
氢化可的松 1.5
地塞米松5
D-泛酸钙1
硫酸钴20
硝酸钾0.6
肌醇100
酚红15
孕酮0.005
磷酸二氢钙5
谷胱甘肽20
丙酮酸120
葡萄糖酸锰0.05
亚硒酸钠0.06
延胡索酸1
甜菜碱11
半胱胺0.05
核黄素2.2
磷酸吡哆醛5
吡啶甲酸铬 5
硒代甲硫氨酸0.001;
其中,组分二包括如下组分:
草酰乙酸500
碳酸氢钠2800
无水磷酸二氢钠2250
氯化钙210
氯化钠4200
氯化钾350
磷酸二氢钾10
无水硫酸镁20
L盐酸精氨酸150
L天冬氨酸50
L天冬酰胺30
L胱氨酸二盐酸盐20
L谷氨酸12
L亮氨酸48
L异亮氨酸100
L甲硫氨酸5
L苯丙氨酸44
L丝氨酸10
L苏氨酸10
L色氨酸5
L缬氨酸120
甘氨酸80
L谷氨酰胺300
肉碱盐酸盐1
葡萄糖1500
果糖0.5
葡萄糖酸钙2
视黄醇10
碘化钾2.8
维生素D35
柠檬酸65
琥珀酸盐10
β-胡萝卜素1
力肽500
右旋糖酐0.5
β-巯基乙酸20
吐温8030
烟酰胺10
维生素E5
抗坏血酸20
生物素0.06
氯化胆碱100
乙醇胺3
七水硫酸亚铁150
六水合氯化镁40
丙酮酸钠70
丁酸钠100
亚油酸0.0002
亚麻酸0.07
硫酸铜15
硫酸铁1.3
盐酸吡哆醇5
氢化可的松5
地塞米松0.001
D-泛酸钙6
硫酸钴1
硝酸钾0.1
肌醇2
酚红5
孕酮0.03
磷酸二氢钙0.23
谷胱甘肽5
丙酮酸5
葡萄糖酸锰5
亚硒酸钠0.02
延胡索酸10
甜菜碱20
半胱胺0.07
核黄素0.5
磷酸吡哆醛0.05
吡啶甲酸铬0.32
硒代甲硫氨酸0.05;
上述各组分含量的单位均为mg/L。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010288501.XA CN111518768B (zh) | 2020-04-14 | 2020-04-14 | 一种适用于lmh细胞贴壁培养的低血清培养基及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010288501.XA CN111518768B (zh) | 2020-04-14 | 2020-04-14 | 一种适用于lmh细胞贴壁培养的低血清培养基及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111518768A CN111518768A (zh) | 2020-08-11 |
CN111518768B true CN111518768B (zh) | 2023-11-21 |
Family
ID=71902170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010288501.XA Active CN111518768B (zh) | 2020-04-14 | 2020-04-14 | 一种适用于lmh细胞贴壁培养的低血清培养基及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111518768B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114774369B (zh) * | 2022-03-30 | 2023-07-25 | 上海健士拜生物科技有限公司 | 腺病毒生产用无血清培养基及腺病毒生产方法 |
CN115058354B (zh) * | 2022-04-28 | 2024-10-08 | 四川百诺吉科技有限公司 | 一种化学成分明确的猪肺炎支原体培养基及其制备方法 |
CN115505571B (zh) * | 2022-11-24 | 2023-03-10 | 上海倍谙基生物科技有限公司 | 适用于悬浮培养lmh细胞生产禽腺病毒的无血清添加剂 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105154389A (zh) * | 2015-10-15 | 2015-12-16 | 南京三生生物技术有限公司 | 一种适于pk-15细胞生长的低血清无蛋白培养基及其制备方法 |
CN107446892A (zh) * | 2017-08-24 | 2017-12-08 | 乾元浩生物股份有限公司 | 一种lmh细胞的培养方法 |
CN110643568A (zh) * | 2019-09-23 | 2020-01-03 | 山东甲骨文生物科技有限公司 | 一种用于bhk-21细胞培养及相应病毒生产的低血清培养基 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0623635D0 (en) * | 2006-11-27 | 2007-01-03 | Stem Cell Sciences Uk Ltd | Pluripotent cell growth media |
-
2020
- 2020-04-14 CN CN202010288501.XA patent/CN111518768B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105154389A (zh) * | 2015-10-15 | 2015-12-16 | 南京三生生物技术有限公司 | 一种适于pk-15细胞生长的低血清无蛋白培养基及其制备方法 |
CN107446892A (zh) * | 2017-08-24 | 2017-12-08 | 乾元浩生物股份有限公司 | 一种lmh细胞的培养方法 |
CN110643568A (zh) * | 2019-09-23 | 2020-01-03 | 山东甲骨文生物科技有限公司 | 一种用于bhk-21细胞培养及相应病毒生产的低血清培养基 |
Non-Patent Citations (1)
Title |
---|
王祎.动物无血清细胞培养基的研究现状及进展.科教文汇.2008,275-276. * |
Also Published As
Publication number | Publication date |
---|---|
CN111518768A (zh) | 2020-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111518768B (zh) | 一种适用于lmh细胞贴壁培养的低血清培养基及其制备方法 | |
CN105018416B (zh) | 一种悬浮培养bhk-21细胞的无血清无动物源培养基及其配制方法 | |
CN109337861B (zh) | 一种支持产物高表达的cho细胞无血清培养基 | |
CN102827804B (zh) | 适用于Vero细胞微载体悬浮放大培养的培养基及方法 | |
USRE30985E (en) | Serum-free cell culture media | |
CN107460159B (zh) | 无血清、无蛋白补料培养基及其制备方法和运用 | |
CN110894487B (zh) | 一种无血清无蛋白cho细胞培养基及其制备方法、应用 | |
CN101760442A (zh) | 适于mdck细胞大规模贴壁培养和单细胞悬浮培养的无血清培养基 | |
CN111996161B (zh) | 一种cho细胞无血清无蛋白培养基及其用途 | |
CN104357379B (zh) | 干细胞培养基 | |
CN105462912B (zh) | 适用于二倍体细胞培养的无蛋白无血清培养基及应用 | |
CN104911143A (zh) | 一种无蛋白、无水解物的无血清培养基及其制备方法 | |
CN107435037B (zh) | 一种用于bhk细胞的无血清培养基 | |
AU662491B2 (en) | Medium for culture of mammalian cells | |
CN110643568A (zh) | 一种用于bhk-21细胞培养及相应病毒生产的低血清培养基 | |
CN114606200A (zh) | Sp2/0细胞培养基及生产重组犬细小病毒单克隆抗体的方法 | |
CN109988741B (zh) | 一种细胞培养用血清替代物及其制备方法、细胞培养用血清替代组合物、细胞培养基 | |
CN113943694B (zh) | 一种支持多种疫苗细胞贴壁或悬浮培养的通用型无血清培养基及其制备方法 | |
JPS5823784A (ja) | 哺乳動物細胞用培地 | |
CN111500532B (zh) | 心肌细胞诱导和生长培养基 | |
CN107119017B (zh) | 一种骨肉瘤细胞的无血清培养基及其制备方法 | |
CN115058354B (zh) | 一种化学成分明确的猪肺炎支原体培养基及其制备方法 | |
CN108265024B (zh) | 适应mdck细胞全悬浮培养的无血清培养基及其制备方法 | |
CN116478903B (zh) | 一种昆虫细胞无血清培养基及其应用 | |
CN116790483B (zh) | 一种cho细胞无血清培养基及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |